The Natural cAMP Elevating Compound Forskolin in Cancer Therapy: Is It Time?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Cancer is a major public health problem and the second leading cause of mortality around the world. Although continuous advances in the science of oncology and cancer research are now leading to improved outcomes for many cancer patients, novel cancer treatment options are strongly demanded. Naturally occurring compounds from a variety of vegetables, fruits, and medicinal plants have been shown to exhibit various anticancer properties in a number of in vitro and in vivo studies and represent an attractive research area for the development of new therapeutic strategies to fight cancer. Forskolin is a diterpene produced by the roots of the Indian plant Coleus forskohlii. The natural compound forskolin has been used for centuries in traditional medicine and its safety has also been documented in conventional modern medicine. Forskolin directly activates the adenylate cyclase enzyme, that generates cAMP from ATP, thus, raising intracellular cAMP levels. Notably, cAMP signaling, through the PKA‐dependent and/or ‐independent pathways, is very relevant to cancer and its targeting has shown a number of antitumor effects, including the induction of mesenchymal‐to‐epithelial transition, inhibition of cell growth and migration and enhancement of sensitivity to conventional antitumor drugs in cancer cells. Here, we describe some features of cAMP signaling that are relevant to cancer biology and address the state of the art concerning the natural cAMP elevating compound forskolin and its perspectives as an effective anticancer agent. J. Cell. Physiol. 232: 922–927, 2017. © 2016 Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells.
Seamon, K. B., Padgett, W., & Daly, J. W. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.6.3363 · Cited by 1,658 · cited 4×
“Forskolin activation of adenylate cyclase occurs primarily via a direct action of the diterpene on the catalytic subunit of adenylate cyclase enzyme without interacting with cell surface receptors (Seamon et al., 1981; Laurenza et al., 1989; Pinto et al., 2008).”
BackgroundInfluentialProtein phosphatase 2A: a target for anticancer therapy
Perrotti, D., & Neviani, P. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70558-2 · Cited by 400 · cited 1×
“…there is evidence that forskolin treatment dephosphorylates and increases PP2A activity in cancer cells resulting in antitumor effects, dependent on PP2A activation, including additive effects with conventional antineoplastic drugs (Perrotti and Neviani, 2013; Crist obal et al., 2014, 2015).”
BackgroundUltraviolet Radiation, Aging and the Skin: Prevention of Damage by Topical cAMP Manipulation
Amaro-Ortiz, A., Yan, B., & D'Orazio, J. (2014) · Molecules · doi:10.3390/molecules19056202 · Cited by 360 · cited 1×
“…hand, pharmacologic stimulation of cAMP using forskolin has been recently described to protect the skin against UV injury and UV-induced carcinogenesis and proposed as a potential UV-protective strategy in individuals who are fairskinned, sun-sensitive and melanoma prone (Amaro-Ortiz et al., 2014).”
BackgroundTopical drug rescue strategy and skin protection based on the role of Mc1r in UV-induced tanning
D'Orazio, J. A., Nobuhisa, T., Cui, R., Arya, M., Spry, M., Wakamatsu, K., Igras, V., Kunisada, T., Granter, S. R., Nishimura, E. K., et al. (2006) · Nature · doi:10.1038/nature05098 · Cited by 350
Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability
Pattabiraman, D. R., Bierie, B., Kober, K. I., Thiru, P., Krall, J. A., Zill, C., Reinhardt, F., Tam, W. L., & Weinberg, R. A. (2016) · Science · doi:10.1126/science.aad3680 · Cited by 332 · cited 1×
“…of the sensitivity to conventional antineoplastic drugs, and the inhibition of proliferation, motility, and migration in many types of cancer cells (Naviglio et al., 2010; Burdyga et al., 2013; Dong et al., 2015; Follin-Arbelet et al., 2015; Pattabiraman et al., 2016; Perez et al., 2016).”
BackgroundPP2A: Unveiling a Reluctant Tumor Suppressor
Mumby, M. (2007) · Cell · doi:10.1016/j.cell.2007.06.034 · Cited by 295
Activation and Inhibition of Adenylyl Cyclase Isoforms by Forskolin Analogs
Pinto, C., Papa, D., Hübner, M., Mou, T.-C., Lushington, G. H., & Seifert, R. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.131904 · Cited by 82
Cited by
Role of cAMP and phosphodiesterase signaling in liver health and disease
Wahlang, B., McClain, C., Barve, S., & Gobejishvili, L. (2018) · Cellular Signalling · doi:10.1016/j.cellsig.2018.06.005 · Cited by 168
The Hippo Signaling Pathway in Drug Resistance in Cancer
Zeng, R., & Dong, J. (2021) · Cancers · doi:10.3390/cancers13020318 · Cited by 89
EMUDRA: Ensemble of Multiple Drug Repositioning Approaches to improve prediction accuracy
Zhou, X., Wang, M., Katsyv, I., Irie, H., & Zhang, B. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty325 · Cited by 43
Metadata
- Authors
- Sapio, L., Gallo, M., Illiano, M., Chiosi, E., Naviglio, D., Spina, A., & Naviglio, S.
- Venue
- Journal of Cellular Physiology
- Publisher
- Wiley
- Published
- 2016-11-20
- Volume
- 232
- Issue
- 5
- Pages
- 922-927
- ISSN
- 0021-9541 (ISSN-L)
- 1097-4652
- OpenAlex
- W2531502250
- Cited by
- 138
- References
- 7
- FWCI
- 4.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Natural cAMP Elevating Compound Forskolin in Cancer Therapy: Is It Time? https://app.cochat.ai/papers/10.1002/jcp.25650
- The paper
- Sapio, L., Gallo, M., Illiano, M., Chiosi, E., Naviglio, D., Spina, A., & Naviglio, S. (2017). The Natural cAMP Elevating Compound Forskolin in Cancer Therapy: Is It Time? Journal of Cellular Physiology. https://doi.org/10.1002/jcp.25650
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.